Inhibition of FGFR3 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. Twice daily administration of placebo (▴) or 25 mg/kg PD173074 (▪) was initiated when KMS11 tumors were palpable (indicated by arrow). Treatment was continued for 9 days (indicated by bar). (A) Tumor volume (mean ± SD mm³) plotted against time. (B) Survival from day of inoculation until death. Twenty-five mice per treatment were included in the analysis. No effect of PD17074 treatment was noted in 8226 tumors similarly treated (data not shown).